Contributions
Abstract: EP1318
Type: ePoster
Abstract Category: Clinical aspects of MS - 3 Paediatric MS
Objective: To describe depression in Pediatric onset MS (POMS) patient and determine whether it associate with physical performance.
Background: POMS has been shown to lead to significant disability. Patient reported outcome (PRO) measures in POMS have been shown to be associated with disease duration in small series but require validation in longitudinal studies. We aim to determine association between depression and physical performance and potentially reduce disease progression.
Design/methods: POMS patient charts were reviewed for demographics, clinical characteristics, PRO and functional outcome (FO). Patients' demographics, FO and PRO were compared between nonslow and SG (if 7 or more seconds). Both 9 hole peg test (9HPT) and timed 25 foot walk (T25FW) were examined for its associations with clinical depression parameters.
Results: A total of 44 POMS patients' charts were reviewed, overall median (IQR) PHQ9 score was 4.0 (1 to 7), 38.6% was depressed Patient health questionnaire (PHQ9>4), 18.2% had T25FW 7 or higher and 37.5 % of the SG group required assistance with gait and 25% needed assistance with transfers. Both PHQ9 (Spearman r=0.46, p=0.002) and Euro Qol five dimension questionnaire (ED5Q) [r=-0.40, p=0.07] were moderately associated with T25FW, and EQ5D was moderately associated with both non-dominant (r=-0.43) and dominant 9HPT (r=-0.32). Age of onset, gender, and race and disease course was not associated with SG. In addition to older age (Median 33 vs. 21 years), longer disease duration (17.5 vs. 5.9 years) were found in SG group, PHQ9 (6.5 vs 3.0) was also higher in SG, 62.5% in SG and 33.3 in non-SG were depressed (PHQ9>4).
Conclusions: POMS patients commonly had both depression and gait disorder. In addition to age and disease duration which are not modifiable, modifiable psychological status may contribute to quality of life in POMS. POMS rehab may need to consider psychology treatment.
Disclosure: Hong Li: nothing to disclose.
Carolyn Bauer; nothing to disclose.
Dr. Mary Rensel serves as a consultant or speaker for Biogen, Teva, Genzyme and Novartis. She receives grant funding from NMSS.
Abstract: EP1318
Type: ePoster
Abstract Category: Clinical aspects of MS - 3 Paediatric MS
Objective: To describe depression in Pediatric onset MS (POMS) patient and determine whether it associate with physical performance.
Background: POMS has been shown to lead to significant disability. Patient reported outcome (PRO) measures in POMS have been shown to be associated with disease duration in small series but require validation in longitudinal studies. We aim to determine association between depression and physical performance and potentially reduce disease progression.
Design/methods: POMS patient charts were reviewed for demographics, clinical characteristics, PRO and functional outcome (FO). Patients' demographics, FO and PRO were compared between nonslow and SG (if 7 or more seconds). Both 9 hole peg test (9HPT) and timed 25 foot walk (T25FW) were examined for its associations with clinical depression parameters.
Results: A total of 44 POMS patients' charts were reviewed, overall median (IQR) PHQ9 score was 4.0 (1 to 7), 38.6% was depressed Patient health questionnaire (PHQ9>4), 18.2% had T25FW 7 or higher and 37.5 % of the SG group required assistance with gait and 25% needed assistance with transfers. Both PHQ9 (Spearman r=0.46, p=0.002) and Euro Qol five dimension questionnaire (ED5Q) [r=-0.40, p=0.07] were moderately associated with T25FW, and EQ5D was moderately associated with both non-dominant (r=-0.43) and dominant 9HPT (r=-0.32). Age of onset, gender, and race and disease course was not associated with SG. In addition to older age (Median 33 vs. 21 years), longer disease duration (17.5 vs. 5.9 years) were found in SG group, PHQ9 (6.5 vs 3.0) was also higher in SG, 62.5% in SG and 33.3 in non-SG were depressed (PHQ9>4).
Conclusions: POMS patients commonly had both depression and gait disorder. In addition to age and disease duration which are not modifiable, modifiable psychological status may contribute to quality of life in POMS. POMS rehab may need to consider psychology treatment.
Disclosure: Hong Li: nothing to disclose.
Carolyn Bauer; nothing to disclose.
Dr. Mary Rensel serves as a consultant or speaker for Biogen, Teva, Genzyme and Novartis. She receives grant funding from NMSS.